Peacock Tariff Consulting works with Irish pharma exporters (Pfizer, Lilly, Merck, MSD, J&J Irish sites), medical device makers (Boston Scientific, Medtronic Ireland), Irish whiskey producers, and agri-food exporters. Ireland’s pharma exports face the largest single Section 232 pharma exposure in Europe – making this market arguably the most tariff-sensitive in the EU.
Ireland exports roughly $73B to the U.S. annually, dominated by pharmaceuticals from sites for Pfizer, J&J, AbbVie, Eli Lilly, and Merck. Dublin is the decision center for Irish exports and for dozens of U.S. multinationals’ EMEA headquarters. Irish pharma is arguably the most U.S.-tariff-exposed export cluster in Europe.
Peacock Tariff Consulting works with Irish exporters across pharma, MedTech, whiskey, and agri-food.
Irish pharma Section 232 scenarios
Section 232 pharma effective July 31, 2026 with tiered rates affects Irish-manufactured branded patented drugs directly. For Pfizer Ireland, Lilly Cork, Merck/MSD operations, and other Irish pharma sites, the rate exposure is large enough to drive supply chain decisions.
Irish MedTech 232 probe readiness
Boston Scientific Ireland, Medtronic Ireland, and the Irish MedTech cluster face the parallel Section 232 MedTech probe. Scope and rate determination remain pending; scenario modeling is the standard advisory deliverable.
Irish whiskey U.S. tariff playbook
Irish whiskey enters the U.S. under HTS Chapter 22 at MFN rates plus Section 122. Tariff treatment is generally simpler than Scotch whisky – fewer trade-political complications historically.
Transfer pricing and tariff valuation
Irish-headquartered multinationals frequently use transfer pricing structures that interact with customs valuation. Related-party pricing must be substantiated for both tax and customs purposes; misalignment between transfer pricing and customs valuation creates exposure.
Routing via Canada for Irish pharma
Irish pharma routing through Canada – limited applicability since Irish-origin goods do not gain CUSMA preference. But specific configurations involving Canadian-side processing can sometimes produce different U.S. tariff treatment. Case-by-case modeling.
Frequently asked questions
How does Section 232 pharma affect Irish pharma sites?
Branded patented drugs face the new tariff effective July 31, 2026 with tiered rates. Generics and biosimilars are excluded. Irish-manufactured branded drugs are directly affected.
Can Irish-origin goods qualify under any U.S. FTA?
Generally no. Ireland is not party to a U.S. FTA. Goods routed through Canada with substantial transformation can sometimes produce CUSMA-qualifying products in narrow configurations.
Do you work with Irish MedTech firms?
Yes. Boston Scientific Ireland and Medtronic Ireland adjacencies are active engagements; mid-market Irish MedTech firms also fit our profile.
How does transfer pricing affect customs valuation?
Transfer pricing for tax purposes and customs valuation under 19 CFR 152 are separate but interact. Related-party pricing must be substantiated as arms-length for customs purposes regardless of TP positioning.
Are you affiliated with Ibec or Enterprise Ireland?
No. We are independent.
Get started
Book an Irish exporter U.S. tariff review.